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Background and Purpose: Adenosine is a local mediator that regulates physiological
and pathological processes via activation of four GPCRs (A1, A2A, A2B, and A3). We
have investigated the effect of two A1-receptor-selective agonists and the novel A1-
receptor bitopic ligand VCP746 on the rat cardiovascular system.
Experimental Approach: The regional haemodynamic responses of these agonist was
investigated in conscious rats. Male Sprague–Dawley rats (350–450 g) were chroni-
cally implanted with pulsed Doppler flow probes on the renal, mesenteric arteries
and the descending abdominal aorta and the jugular vein and caudal artery cat-
heterized. Cardiovascular responses were measured following intravenous infusion
(3 min each dose) of CCPA (120, 400, and 1,200 ngkg−1min−1), capadenoson or
adenosine (30, 100, and 300 μgkg−1min−1), or VCP746 (6, 20, and 60 μgkg−1min−1)
following pre-dosing with DPCPX (0.1 mgkg−1, i.v.) or vehicle.
Key Results: CCPA produced a significant A1-receptor-mediated decrease in heart
rate that was accompanied by vasoconstrictions in the renal and mesenteric vascular
beds but an increase in hindquarters vascular conductance. The partial agonist
capadenoson also produced an A1-receptor-mediated bradycardia. In contrast,
VCP746 produced increases in heart rate and renal and mesenteric vascular conduc-
tance that were not mediated by A1-receptors. In vitro studies confirmed that
VCP746 had potent agonist activity at both A2A- and A2B-receptors.
Conclusions and Implications: These results suggest VCP746 mediates its cardiovas-
cular effects via activation of A2 rather than A1 adenosine receptors. This has implica-
tions for the design of future bitopic ligands that incorporate A1 allosteric ligand
moieties.
1 | INTRODUCTION
Adenosine is present in all cells in tightly regulated concentrations
(Borea, Gessi, Merighi, Vincenzi, & Varani, 2018; Fredholm, Ijzerman,
Jacobson, Linden, & Müller, 2011). It is released under a variety of
Abbreviations: A1-receptor, A1 adenosine receptor; Capadenoson, 2-amino-
6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]
pyridine-3,5-dicarbonitrile; CCPA, (2-chloro-N6-cyclopentyladenosine); DPCPX, 1,3-dipropyl-
8-cyclopentylxanthine; NECA, 50-(N-ethylcarboxamido)adenosine; VCP171, (2-amino-
4-(3-(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)methanone; VCP746, 4-(5-amino-
4-benzoyl-3-(3-(trifluoromethyl)phenyl)thiophen-2-yl)-N-(6-(9-((2R,3R,4S,5R)-3,4-dihydroxy-
5-(hydroxylmethyl)tetrahydro-furan-2-yl)-9H-purin-6-ylamino)hexyl)benzamide.
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physiological and pathophysiological conditions to facilitate protection
and regeneration of tissues (Borea et al., 2018; Fredholm et al., 2011;
Müller & Jacobson, 2011). Adenosine acts via four different GPCRs
(A1, A2A, A2B, and A3) to mediate its physiological effects. A1- and A3-
receptors are Gi/o-coupled and mediate responses primarily via inhi-
bition of AC activity and/or inhibition of neurotransmitter release
(Fredholm et al., 2011; Hill, May, Kellam, & Woolard, 2014; Müller &
Jacobson, 2011). A2A- and A2B-receptors are Gs-coupled and mediate
their effects primarily via stimulation of AC activity (Borea et al.,
2018; Fredholm et al., 2011; Müller & Jacobson, 2011).
In the heart, adenosine A1-receptor activation results in negative
inotropic, chronotropic, and dromotropic effects (Borea et al., 2018;
Fenton & Dobson, 2007; Headrick, Peart, Reichelt, & Haseler, 2011).
In addition, it has been shown that selective A2A adenosine receptor
agonists are potent vasodilators in the rat that reduce BP and induce
marked increases in heart rate and plasma renin activity (Alberti et al.,
1997). The A2A effect on heart rate appears to be secondary to an
increase in reflex sympathetic nervous activity (Alberti et al., 1997).
Previous work in conscious rats has also shown that an A1-selective
agonist can cause significant decreases in heart rate, a fall in mean
arterial pressure and vasoconstriction in both the renal and mesen-
teric vascular beds, but vasodilatation in the hindquarters (Jolly,
March, Kemp, Bennett, & Gardiner, 2008).
A number of selective agonists and antagonists are now
available for the A1-receptor (Borea et al., 2018; Fredholm et al.,
2011; Müller & Jacobson, 2011). Some A1-receptor-selective
agonists and partial agonists have undergone evaluation for cardiovas-
cular disease indications such as paroxysmal supraventricular tachy-
cardia, atrial fibrillation, angina pectoris and heat failure (Meibom
et al., 2017; Müller & Jacobson, 2011). However, the ubiquitous distri-
bution of adenosine receptors in the body can often limit therapeutic
application because of the effects of adenosine receptor ligands on
the same receptor in a different tissue or cell type (Müller &
Jacobson, 2011).
One way in which the activity of endogenous adenosine can be
subtly regulated at the level of its target receptor is via drugs that bind
to an allosteric site on the receptor protein of interest. These allosteric
modulators act to enhance or inhibit the binding of adenosine to its
receptor binding site (the orthosteric site) and/or change the resulting
functional response (Keov, Sexton, & Christopoulos, 2010; Hill et al.,
2014; Göblyös & IJzerman, 2011; Kimatrai-Salvador, Baraldi, &
Romagnoli, 2012; Cooper et al., 2019). VCP171, (2-amino-
4-(3-(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)methanone, has
been described as a novel positive allosteric modulator for the adeno-
sine A1-receptor (Aurelio et al., 2009, 2010; Imlach, Bhola, May,
Christopoulos, & Christie, 2015; Valant et al., 2010; Vincenzi et al.,
2014). Recently, a hybrid molecule (or bitopic ligand) has been
described that comprises adenosine attached via a linker to this posi-
tive allosteric modulator (Valant et al., 2014). The resulting hybrid
ligand (VCP746) has been suggested to exhibit signalling bias towards
Gi-mediated signalling and furthermore was also able to protect
against ischaemic damage in cardiomyocytes expressing native A1-
receptors (Valant et al., 2014). It did not, however, alter heart rate in
an isolated rat atrial preparation (Valant et al., 2014). VCP746 has also
been shown to reduce cardiac myocyte hypertrophy and remodelling
(Chuo et al., 2016).
In the present study, we have used a Doppler flow in vivo model
for the simultaneous measurement of vascular conductance in three
distinct vascular beds, heart rate and BP in conscious freely moving
rats, to compare the cardiovascular effects of a full A1-receptor-
selective agonist CCPA, a partial agonist capadenoson (Tendera et al.,
2012) and VCP746 (Figure 1). This allows us to evaluate the impact of
adenosine receptor bitopic ligand VCP746 on cardiovascular
responses in an animal model subject to normal autonomic regulation.
2 | METHODS
2.1 | Drugs, chemical reagents and other material
Adenosine receptor ligands, adenosine (Cat# A9251) and 50-N-
ethylcarboxamidoadenosine (NECA; Cat# E2387) were purchased
from Sigma-Aldrich (Gillingham, UK). 1,3-Dipropyl-
8-cyclopentylxanthine (DPCPX; Cat# C101) and 2-chloro-N6-
cyclopentyladenosine (CCPA; Cat# C7938) were purchased from
Tocris Bioscience (Bristol, UK). (2-Amino-4-(3-(trifluoromethyl)phenyl)
thiophen-3-yl)(phenyl)methanone (VCP171) and 4-(5-amino-4-
benzoyl-3-(3-(trifluoromethyl)phenyl)thiophen-2-yl)-N-(8-(9-((2R,3R,
4S,5R)-3,4-dihydroxy-5-(hydroxylmethyl)tetrahydro-furan-2-yl)-9H-
purin-6-ylamino)hexyl)benzamide (VCP746) were synthesized as pre-
viously described by Aurelio et al. (2009) and Valant et al. (2014),
respectively. 2-Amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl-
sulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile
(capadenoson) was purchased from Haoyuan Chemexpress (Cat# HY-
14917; Shanghai, China).
What is already known
• Adenosine is a local mediator that regulates physiological
processes via stimulation of the adenosine A1-receptor.
• VCP746 is adenosine linked to an A1-allosteric enhancer
(VCP171), reported to be a biased A1-agonist.
What this study adds
• VCP746 causes increases in heart rate and vascular con-
ductance that are not mediated by A1-receptors.
• Reporter gene studies confirm that VCP746 is a potent
agonist of both A2A- and A2B-receptors.
What is the clinical significance
• The adenosine receptor subtype selectivity of the bitopic
ligand VCP746 and its cardiovascular action have been
clarified.
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Fentanyl citrate was purchased from Jansen-Cilac Ltd,
UK. Medetomidine (Domitor), meloxicam, and atipamezole hydrochlo-
ride (Antisedan) were purchased from Pfizer, UK. Buprenorphine
(Vetergesic) and pentobarbitone (Euthatal) were purchased from
Alstoe Animal Health, UK. Tween and propylene glycol were pur-
chased from Sigma-Aldrich, UK.
2.2 | CRE-SPAP gene transcription assay for
adenosine A2A- and A2B-receptor agonist activity in
CHO-K1 cells
CHO-K1 cells (RRID-CVCL_0214) expressing a cAMP response ele-
ment (CRE) regulated secreted placental alkaline phosphate (SPAP)
reporter gene and the human adenosine A2A-receptor or human aden-
osine A2B-receptor were generated and grown to confluence in clear
96-well plates as described previously (Stoddart, Vernall, Briddon,
Kellam, & Hill, 2015). On the day prior to analysis, normal growth
medium was removed and replaced with serum-free medium (SFM;
DMEM/F12 supplemented with 2-mM L-glutamine). On the day of
the experiment, fresh SFM was added to the cells with increasing con-
centrations of the required test compounds. CRE-SPAP cells were
then incubated for 5 hr at 37C in humidified air containing 5% CO2.
After 5-hr incubation, all medium was removed from the cells and rep-
laced with 40 μl of SFM and incubated for a further 1 hr. The plates
were then incubated at 65C for 30 min to destroy the endogenous
alkaline phosphatases. After cooling the plates to room temperature,
100 μl of 5-mM 4-nitrophenyl phosphate in a diethanolamine-
containing buffer (10% (v/v) diethanolamine, 280-mM NaCl, 500-mM
MgCl2, pH 9.85) was then added to each well. Plates were incubated
for varying times depending on the cell line (CHO-A2A, 25 min at
37C; CHO-A2B, overnight at room temperature) and then the absor-
bance at 405 nm was measured using a Dynex MRX plate reader
(Chelmsford, MA, USA). Five independent experiments were con-
ducted using quadruplicate repeats to ensure the reliability of single
values.
2.3 | Animals and surgery
Adult male Sprague–Dawley rats weighing 350 to 450 g were pur-
chased from Charles River Laboratories, UK. Animals were pair housed
in standard, individually ventilated cages prepared with bedding mate-
rial and enrichment. Cages were held in a temperature-controlled (21–
23C) environment with a 12-hr light–dark cycle (lights on at
6:00 a.m.), and animals received access to food (18% Protein Rodent
Diet; Envigo, Madison WI, USA) and water ad libitum for at least
7 days before any surgical intervention. All procedures were approved
by the Animal Welfare and Ethical Review Body (University of Not-
tingham; which has representation from NC3Rs) and performed in
keeping with the Animals (Scientific Procedures) Act (1986), under UK
Home Office approved Project Licence and Personal License authority
(PPL 40/3680). Forty five rats were used for this study, and results are
recorded in accordance with the ARRIVE guidelines for reporting
experiments involving animals (McGrath, Drummond, McLachlan, Kil-
kenny, & Wainwright, 2010). Animal studies are reported in compli-
ance with the ARRIVE guidelines (Kilkenny et al., 2010) and the
editorial on reporting animal studies (McGrath & Lilley, 2015), with
the recommendations made by the British Journal of Pharmacology.
2.4 | Doppler flow probe implantation
Surgery was performed under general anaesthesia (fentanyl and med-
etomidine, 300 μgkg−1 each, i.p., supplemented as required), with
reversal of anaesthesia and postoperative analgesia provided by
F IGURE 1 Chemical structures of adenosine,
capadenoson, CCPA, VCP171 and VCP746. In the
case of VCP746, the adenosine and VCP171
component of the structure are shown in blue and
red, respectively
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atipamezole hydrochloride (1 mgkg−1, s.c.) and buprenorphine
(30 μgkg−1, s.c.). A second dose of buprenorphine (15 μgkg−1, s.c.)
was given as an analgesic 4 hr after surgery.
A midline incision was performed and miniature pulsed Doppler
flow probes were sutured around the left renal and superior mesen-
teric arteries and the descending abdominal aorta (providing blood to
the hindquarters) to monitor vascular conductance (VC; Carter,
Fretwell, & Woolard, 2017). The probe wires were secured to the left
abdominal wall and tunnelled via the left flank to the posterior of the
neck. The wires were then secured with suture and sterile tape to the
nape of the neck. Following surgery, animals were returned to home
cages with access to food and water and received analgesia
(meloxicam 1 mgkg−1day−1) for 3 days.
2.5 | Catheter implantation
Catheter implantation commenced at least 10 days after the Doppler
flow probe implantation surgery and after a satisfactory
inspection from the Named Veterinary Surgeon. Under anaesthesia
(as described above) catheters filled with heparinised saline
(15 Uml−1) were implanted into the distal abdominal aorta, via
the ventral caudal artery (for the measurement of arterial BP
and heart rate) and implanted into the right jugular vein (for
drug administration; Carter et al., 2017). Three separate intravenous
catheters were placed in the jugular vein to enable
independent administration of different substances. At this stage, the
probe wires were soldered into a miniature plug (Omnetic Connector
Corporation, USA), which was mounted onto a custom-designed har-
ness worn by the rat. The catheters emerged from the same point as
the probe wires and were fed through a protective spring secured to
the harness and attached to a counterbalanced pivot system. Reversal
of anaesthetic and analgesia was administered (as described above)
and the animals were single housed with free access to food and
water. The arterial catheter was connected to a fluid-filled swivel for
overnight infusion of heparinised (15 Uml−1) saline to maintain
potency.
Experiments began 24 hr after surgery for catheter implantation,
with animals fully conscious and unrestrained in home cages and with
free access to food and water.
2.6 | Cardiovascular recordings
Haemodynamic variables (heart rate, arterial BP, renal, mesenteric,
and hindquarters Doppler shifts) were recorded using a customized,
computer-based system (IdeeQ; Maastricht Instruments, Maastricht,
The Netherlands) that connected a transducer amplifier (13-4615-50;
Gould, Cleveland, OH, USA), a Doppler flowmeter (Crystal Biotech,
Holliston, MA, USA), and a VF-1 mainframe (pulse repetition fre-
quency 125 kHz) fitted with high-velocity (HVPD-20) modules. Raw
data were sampled by IdeeQ every 2 ms, averaged, and stored to disc
every cardiac cycle. Changes in renal VC (RVC), mesenteric VC (MVC),
and hindquarter VC (HVC), in the renal, mesenteric, and hindquarter
vascular beds, respectively, were calculated from the changes in mean
arterial pressure (MAP) and Doppler shift. At the end of each experi-
ment, rats were killed by a schedule one procedure, with Euthatal
(60–80 mg, i.p.) and exsanguination.
2.7 | Experimental protocol
Experiments were run in six studies, each lasting 3 days; within each
study was a contemporaneous vehicle control (5% propylene glycol,
2% Tween 80 in sterile saline). Power calculations were performed to
estimate appropriate group sizes, and experiments were generally run
with treatment groups of six to eight rats. Animals were randomly
allocated to antagonist or vehicle on day 1 and the alternative treat-
ment then given on day 3.
2.7.1 | Study 1
Eight animals were used to assess the cardiovascular responses to
CCPA in the presence or absence of DPCPX. After a period of base-
line recordings, rats were randomized into two groups. Group 1
received vehicle intravenous bolus (0.1 ml provided over 5 s) on day
1 and a DPCPX (0.1 mgkg−1) intravenous bolus on day 3. Group 2
received DPCPX (0.1 mgkg−1, 0.1-ml bolus, i.v.) on day 1 and a vehicle
(0.1-ml bolus, i.v.) on day 3. Approximately 10 min after the initial
bolus of vehicle or DPCPX, all groups received intravenous infusions
(0.1 mlmin−1) of CCPA (120 [low], 400 [mid], and 1,200 [high]
ngkg−1min−1) on both day 1 and day 3. Each dose was infused for
3 min. Haemodynamic recordings were made for a further 4 hr follow-
ing the completion of the CCPA intravenous infusion period.
2.7.2 | Study 2
Seven animals were used to measure the cardiovascular responses to
capadenoson in the presence or absence of DPCPX. Following a
period of baseline, rats were randomized into two groups. Group 1
received vehicle (0.1 ml bolus, i.v.) on day 1 and DPCPX (0.1 mgkg−1
bolus, i.v.) on day 3. Group 2 received a single 0.1 ml bolus of DPCPX
(0.1 mgkg−1, i.v.) on day 1 and vehicle (bolus, 0.1 ml) on day 3. After
10 min, all groups received intravenous infusions (0.1 mlmin−1) of
capadenoson (30 [low], 100 [mid], and 300 [high] μgkg−1min−1) on
day 1 and day 3. Each dose of capadenoson was given as a 3-min infu-
sion. Cardiovascular recordings were continued for a further 4 hr after
administration of capadenoson.
2.7.3 | Study 3
Eight animals were used to assess the cardiovascular responses to
VCP746 (Valant et al., 2014) in the presence or absence of
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DPCPX. Following a period of baseline, rats were randomized into
two groups. Group 1 received vehicle (0.1 ml bolus, i.v.) on day
1 and DPCPX (0.1 mgkg−1 bolus, i.v.) on day 3. Group 2 received
a single 0.1 ml bolus of DPCPX (0.1 mgkg−1, i.v.) on day 1 and
vehicle (bolus, 0.1 ml) on day 3. Approximately 10 min after the
initial bolus, all groups received intravenous infusions (0.1 mlmin−1)
of VCP746 (6 [low], 20 [mid], and 60 [high] μgkg−1min−1) on day
1 and day 3. Each dose of VCP746 was given as a 3-min infusion.
Cardiovascular recordings were continued for a further 4 hr after
administration of the VCP746.
2.7.4 | Study 4
Eight animals were used to assess the cardiovascular responses to
adenosine in the presence or absence of DPCPX. Following a period
of baseline, rats were randomized into two groups. Group 1 received
vehicle (0.1 ml bolus, i.v.) on day 1 and DPCPX (0.1 mgkg−1 bolus, i.v.)
on day 3. Group 2 received a single 0.1 ml bolus of DPCPX
(0.1 mgkg−1, i.v.) on day 1 and vehicle (bolus, 0.1 ml) on day
3. After 10 min, all groups received intravenous infusions
(0.1 mlmin−1) of adenosine (30 [low], 100 [mid], and 300 [high]
μgkg−1min−1) on day 1 and day 3. Each dose of adenosine was
given as a 3-min infusion. Cardiovascular recordings were continued
for a further 4 hr after administration of the adenosine.
2.7.5 | Study 5
Seven animals were used to assess the cardiovascular responses to
VCP171 (Aurelio et al., 2009) in the presence or absence of DPCPX.
Following a period of baseline, rats were randomized into two groups.
Group 1 received vehicle (0.1 ml bolus, i.v.) on day 1 and DPCPX
(0.1 mgkg−1 bolus, i.v.) on day 3. Group 2 received a single 0.1 ml
bolus of DPCPX (0.1 mgkg−1, i.v.) on day 1 and vehicle (bolus, 0.1 ml)
on day 3. After 10 min, all groups received intravenous infusions
(0.1 mlmin−1) of VCP171 (2.6 [low], 8.5 [mid], and 25.6 [high]
μgkg−1min−1) on day 1 and day 3. Each dose of VCP171 was given
as a 3 min infusion. Cardiovascular recordings were continued for a
further 4 hr after administration of the adenosine.
2.7.6 | Study 6
Seven animals were used to assess the cardiovascular responses to
adenosine in the presence or absence of VCP171. Following a
period of baseline, rats were randomized into two groups. Group 1
received a 14-min infusion of vehicle (0.1 mlmin−1, i.v.) on day
1 and a 14-min infusion of VCP171 (25.6 μgkg−1min−1, i.v.) on day
3. Group 2 received a 14-min infusion of VCP171
(25.6 μgkg−1min−1, i.v.) on day 1 and a vehicle infusion
(0.1 mlmin−1) on day 3. After 5 min of the VCP171 or vehicle infu-
sion, all groups received intravenous infusions (0.1 mlmin−1) of
adenosine (30 [low], 100 [mid], and 300 [high] μgkg−1min−1) on day
1 and day 3. Each dose of adenosine was given for 3 min. Cardio-
vascular recordings were continued for a further 4 hr after adminis-
tration of the adenosine.
2.8 | Data analysis
All in vivo data were collected and analysed using IdeeQ software 2.5
(Maastricht Instruments, Maastricht University, NL). For all experi-
ments, time-averaged data are shown as changes from baseline [heart
rate (HR) (beatsmin−1); MAP (mmHg); VC (%)]. Statistical analysis
used BIO-medical software 3.4 (Medical Physics, University of Not-
tingham, UK). Statistical comparisons between groups of animals were
performed on the integrated changes over specified time periods. A
Friedman test, which is a nonparametric, repeated-measures ANOVA
was used for within-group comparisons and a Wilcoxon rank-sum test
for integrated area under or above curve analysis was used for com-
parisons between groups. A Wilcoxon test was also performed for
comparisons between groups at a specific time point. Vascular con-
ductances were calculated from the MAP and Doppler shift (flow)
data. It is worth noting that the Friedman test is a non-parametric sta-
tistical test which involves ranking each row and then comparing the
values of ranked columns, to detect differences in treatments across
multiple time points. Variability within the row can therefore affect
the level of significance. Thus, certain points of significance over a
period of 10 min may not always retain significant when analysed
over the extended 240 min (e.g., when comparing (a) and (b) in Fig-
ures 2, 5–8). For this reason, statistical analysis was performed over
both time periods.
Statistical analysis of the combine data for vehicle (n = 38) and
DPCPX alone (n = 38) from all studies was also analysed by Wilcoxon
signed rank test for differences between groups at a specific time
point and Friedman's test to test for within-group differences from
the time zero point using Prism 7.0 (GraphPad Software, San Diego,
CA, USA). Prism 7.0 was used instead of BIO-medical software due to
the large number of data sets used.
Concentration–response curves for agonist-mediated CRE-SPAP
gene expression were fitted using non-linear regression (Prism 7.0,
GraphPad Software, San Diego, CA, USA) to the following
equation:
Response=
Emax × A½ 
A½ +EC50 ,
where Emax is the maximal response, [A] is the concentration of ago-
nist, and the EC50 is the molar concentration of agonist required to
generate 50% of the Emax. Statistical analysis of concentration–
response data was analysed by one-way ANOVA using Prism 7.0. For
all statistical analysis, a value of P < .05 was considered significant.
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analy-
sis in pharmacology (Curtis et al., 2018).
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2.9 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018) and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18 (Alexander,
Christopoulos, et al., 2017; Alexander, Fabbro, et al., 2017).
3 | RESULTS
Baseline cardiovascular variables before the administration of
1,3-dipropyl-8-cyclopentylxanthine (DPCPX), adenosine
receptor agonists and their corresponding vehicles controls are shown
in Table 1.
3.1 | Effect of 2-chloro-N6-
cyclopentyladenosine (CCPA)
Intravenous infusion of increasing concentrations of the
adenosine A1-receptor-selective agonist CCPA (120, 400 and
1,200 ngkg−1min−1; 3-min infusions of each dose) produced a sig-
nificant dose-dependent decrease (P < .05) in heart rate and MAP
(Figure 2a,b). This was accompanied by vasoconstriction in both
the renal and mesenteric vascular beds, but a small vasodilatation
in the hindquarters (P < .05; Figure 2a,b). The increase in VC in
the hindquarters (monitored via the Doppler probe on the des-
cending abdominal aorta) developed more slowly than the vasocon-
striction observed in the renal and mesenteric vascular beds and
reached a peak at 10 min which, unlike the effects on HR and
renal or mesenteric VC, was maintained for a further 10 min
(Figure 2b). The fall in MAP also developed more slowly and was
sustained until the 20-min time point (Figure 2b). A role for adeno-
sine A1-receptors in these cardiovascular responses was confirmed
by pre-treating animals with a bolus intravenous injection of the
A1-selective antagonist DPCPX (0.1 mgkg−1, i.v.) prior to the addi-
tion of CCPA. DPCPX pretreatment significantly attenuated
(P < .05) the CCPA-induced effects on HR, MAP and VC in the
renal and mesenteric vascular beds (Figure 2a,b). The effect of
DPCPX on the effect of CCPA on HVC did not reach significance
(Figure 2a,b).
The effect of DPCPX alone was evaluated for 5 min (relative to
a vehicle control) prior to agonist administration in all five of the
studies involving DPCPX described under Section 2. Figure 3 shows
the combined data for DPCPX and vehicle from all of the studies.
Administration of DPCPX produced a small increase in HR and MAP
consistent with antagonism of a small contribution to basal activity
from an A1-receptor-mediated response to endogenous adenosine
(Figure 3). There was also a small direct effect of DPCPX on MVC
(Figure 3). A similar effect on MVC has been previously reported by
F IGURE 2 Cardiovascular
responses to CCPA in the
presence or absence of DPCPX, in
conscious freely moving rats. Rats
were dosed with either DPCPX
(0.1 ml bolus dose of 0.1 mgkg−1,
i.v., n = 8) or vehicle (0.1 ml bolus
dose of 5% propylene glycol, 2%
Tween 80 in sterile saline, n = 8),
as described under Section 2.
Approximately 10 min later, all
animals received an infusion of
CCPA (120 [low], 400 [mid] and
1,200 [high] ngkg−1min−1; each
dose infused over 3 min). Time
course is shown during (a) the
treatment period and (b) over the
extended 4-hr recording period.
Data points are mean and vertical
bars represent SEM. *P < .05
versus baseline (Friedman's test).
θ significant difference between
groups comparison (P < .05;
Wilcoxon signed rank test,
0–5 min) based on integrated area
under or above curve analysis. A
Wilcoxon test was also conducted
between treated and vehicle
controls at each time
point (#P < .05)
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Jolly et al. (2008) who also found that mesenteric vasoconstrictor
effects of DPCPX were reduced by losartan suggesting that it may
be, at least in part, secondary to antagonism of A1-receptor-mediated
effects of endogenous adenosine on renin release (Jackson, 1991;
Tagawa & Vander, 1970).
3.2 | Effect of the A1-receptor-selective partial
agonist capadenoson
Capadenoson is a selective A1-receptor partial agonist (Albrecht-
Kupper, Leineweber, & Nell, 2012) that may have clinical utility in
conditions such as angina (Tendera et al., 2012). Intravenous infusion
of increasing concentrations of capadenoson (30, 100 and
300 μgkg−1min−1; 3-min infusions of each dose) produced a signifi-
cant dose-dependent decrease (P < .05) in HR that reached a peak
at 20 min (Figure 4a,b). This was not accompanied by any
significant changes in MAP or renal and mesenteric VC (Figure 4a,b).
There was, however, a small vasodilatation in the hindquarters
F IGURE 3 Cardiovascular responses to DPCPX, in conscious
freely moving rats. Rats were dosed with either DPCPX (0.1 ml bolus
dose of 0.1 mgkg−1 i.v., n = 38) or vehicle (0.1 ml bolus dose of 5%
propylene glycol, 2% Tween 80 in sterile saline, n = 38), as described
under Section 2. The time course shows responses over the 5-min
period, post-dosing. Data points are mean and vertical bars represent
SEM. *P < .05 versus baseline (Friedman's test). A Wilcoxon signed
rank test was also conducted between treated and vehicle controls at
each time point (#P < .05)
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(Figure 4). Pretreatment with DPCPX prevented the A1-receptor-
mediated decrease in HR caused by capadenoson and revealed a small
increase in RVC and a vasoconstriction in the mesenteric vascular bed
(Figure 4a,b).
3.3 | Effect of the bitopic A1-receptor ligand
VCP746 on cardiovascular responses in the rat
VCP746 is a hybrid molecule containing the adenosine moiety linked
to the positive A1-receptor allosteric modulator VCP171 (Figure 1). It
has been previously reported to act as a biased A1-receptor agonist
that has no direct negative chronotropic effect in isolated rat atria
(Valant et al., 2014). Application of VCP746 (6, 20 and
60 μgkg−1min−1, i.v.; 3-min infusion), however, produced a significant
(P < .05) increase in HR in conscious freely moving rats that occurred
in parallel with marked increases in renal and mesenteric vascular con-
ductance (Figure 5a,b). These effects of VCP746 were not significantly
antagonized by the A1-selective antagonist DPCPX (Figure 5a,b).
3.4 | Effect of adenosine, VCP171 and both in
combination
To investigate the extent to which the cardiovascular responses to
VCP746 observed above are due to the component molecules (adeno-
sine and VCP171) contained within VCP746, we have studied
their effect on the cardiovascular system alone and in combination.
The endogenous ligand adenosine (30, 100 and 300 μgkg−1min−1;
3-min intravenous infusion) produced a similar cardiovascular profile,
in terms of a significant (P < .05) increase in HR, and associated
increases in renal and mesenteric VC, to that observed with VCP746
(Figure 6a,b). In addition, adenosine also produced a significant fall in
MAP (P < .05) and a large increase in HVC (P < .05; Figure 6a,b). Non-
e of the cardiovascular responses to adenosine were prevented by
pretreatment with DPCPX. Following infusion of adenosine
(Figure 6b), MAP returned to normal levels 60 min after cessation of
the adenosine infusion. However, in DPCPX-treated animals MAP
remained slightly lower in the DPCPX-treated group than in the vehi-
cle controls (Figure 6b). It should be noted, however, that this
effect of DPCPX on MAP was only a small and a significant effect of
DPCPX treatment was not observed following similar protocols using
VCP746, capadenoson or CCPA in place of adenosine (Figures 2, 4,
and 5).
The effect of VCP171 alone was investigated at equivalent equi-
molar doses to those at which the parent hybrid molecule VCP746
elicited significant effects on heart rate and renal/mesenteric VC. The
doses chosen were based on the fraction of the MW of VCP746 that
was contributed by the VCP171 component (Figure 1). Infusion of
VCP171 (2.6, 8.5 and 25.6 μgkg−1min−1; 3-min intravenous infu-
sions) produced a small decrease in VC in the mesenteric vascular bed
(P < .05) but no consistent effect on heart rate or renal and hindquar-
ters VC (Figure 7a,b). The reduction in mesenteric VC was not antago-
nized by DPCPX (Figure 7a,b).
F IGURE 4 Cardiovascular responses to capadenoson in the presence or absence of DPCPX, in conscious freely moving rats. Rats were dosed
with either DPCPX (0.1 ml bolus dose of 0.1 mgkg−1 i.v., n = 7) or vehicle (0.1 ml bolus dose of 5% propylene glycol, 2% Tween 80 in sterile
saline, n = 7), as described under Section 2. Approximately 10 min later, all animals received an infusion of capadenoson (30 [low], 100 [mid], and
300 [high] μgkg−1min−1; each dose infused over 3 min). Time course is shown during (a) the treatment period and (b) over the extended 4-hr
recording period. Data points are mean and vertical bars represent SEM. *P < .05 versus baseline (Friedman's test). A Wilcoxon signed rank test
was also conducted between treated and vehicle controls at each time point (#P < .05)
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F IGURE 5 Cardiovascular responses to VCP746 in the presence or absence of DPCPX, in conscious freely moving rats. Rats were dosed with
either DPCPX (0.1 ml bolus dose of 0.1 mgkg−1 i.v., n = 8) or vehicle (0.1 ml bolus dose of 5% propylene glycol, 2% Tween 80 in sterile saline,
n = 8), as described under Section 2. Approximately 10 min later, all animals received an infusion of VCP746 (6 [low], 20 [mid], and 60 [high]
μgkg−1min−1; each dose infused over 3 min). Time course is shown during (a) the treatment period and (b) over the extended 4-hr recording
period. Data points are mean and vertical bars represent SEM. *P < .05 versus baseline (Friedman's test). A Wilcoxon signed rank test was also
conducted between treated and vehicle controls at each time point (#P < .05)
F IGURE 6 Cardiovascular responses to adenosine in the presence or absence of DPCPX, in conscious freely moving rats. Rats were dosed
with either DPCPX (0.1-ml bolus dose of 0.1 mgkg−1 i.v., n = 8) or vehicle (0.1 ml bolus dose of 5% propylene glycol, 2% Tween 80 in sterile
saline, n = 8), as described under Section 2. Approximately 10 min later, all animals received an infusion of adenosine (30 [low], 100 [mid], and
300 [high] μgkg−1min−1; each dose infused over 3 min). Time course is shown during (a) the treatment period and (b) over the extended 4-hr
recording period. Data points are mean and vertical bars represent SEM. *P < .05 versus baseline (Friedman's test). A Wilcoxon signed rank test
was also conducted between treated and vehicle controls at each time point (#P < .05)
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In combination, adenosine and VCP171 produced essentially simi-
lar cardiovascular responses to those obtained with adenosine alone
(Figure 8a,b). In the presence of VCP171, there was a hint that the
increase in heart rate produced by adenosine was somewhat blunted,
perhaps consistent with an enhanced contribution of a minor A1-
receptor-mediated bradycardia (Figure 8a,b).
F IGURE 7 Cardiovascular responses to VCP171 in the presence or absence of DPCPX, in conscious freely moving rats. Rats were dosed with
either DPCPX (0.1 ml bolus dose of 0.1 mgkg−1, i.v., n = 7) or vehicle (0.1 ml bolus dose of 5% propylene glycol, 2% Tween 80 in sterile saline,
n = 7), as described under Section 2. Approximately 10 min later, all animals received an infusion of VCP171 (2.6 [low], 8.5 [mid], and 25.6 [high]
μgkg−1min−1; each dose infused over 3 min). Time course is shown during (a) the treatment period and (b) over the extended 4-hr recording
period. Data points are mean and vertical bars represent SEM. *P < .05 versus baseline (Friedman's test). A Wilcoxon signed rank test was also
conducted between treated and vehicle controls at each time point (#P < .05)
F IGURE 8 Cardiovascular
responses to adenosine in the
presence or absence of VCP171,
in conscious freely moving rats.
Rats were dosed with either
VCP171 (25.6 μgkg−1min−1,
i.v. for 14 min, n = 7) or vehicle
(0.1 mlmin−1 dose over 14 min of
5% propylene glycol, 2% Tween
80 in sterile saline, n = 7), as
described under Section 2.
Approximately 5 min into the
infusion, all animals received an
infusion of adenosine (30 [low],
100 [mid], and 300 [high]
μgkg−1min−1; each dose infused
over 3 min). Time course is shown
during (a) the treatment period
and (b) over the extended 4-hr
recording period. Data points are
mean and vertical bars represent
SEM. *P < .05 versus baseline
(Friedman's test). A Wilcoxon
signed rank test was also
conducted between treated and
vehicle controls at each time
point (#P < .05)
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3.5 | Agonist effect of VCP746 on adenosine A2A-
and A2B-receptor-mediated CRE-SPAP responses
The lack of effect of the A1-antagonist DPCPX on the cardiovascular
responses to VCP746, and their similarity with those obtained with
adenosine, suggests that VCP746 is able to stimulate other adenosine
receptors in the cardiovascular system. It has previously been shown
that VCP746 lacks agonist efficacy at adenosine A3-receptors (Valant
et al., 2014). Vecchio et al. (2016) have recently shown that VCP746
is a high affinity and potent agonist of A2B-receptors. However, the
potent vasodilator and tachycardia effects of VCP746 observed in the
present study were more consistent with an effect on A2A-receptors
(Alberti et al., 1997; Borea et al., 2018; Headrick, Ashton, Meyer, &
Peart, 2013). As a consequence, we have evaluated the agonist effect
of VCP746 on CRE-mediated reporter gene responses in CHO-K1
cells stably expressing either the human A2A-receptor or the human
A2B-receptor (Figure 9). Consistent with previous reports (Vecchio
et al., 2016), VCP746 was a potent and efficacious agonist of A2B-
receptor-mediated CRE-gene expression (pEC50 = 8.7 ± 0.1,
Emax = 103.0 ± 4.6% of response to 1-μM NECA, n = 5; Figure 9;
Table 2). VCP746 was, however, also a potent and high efficacy
agonist of A2A-receptor-mediated CREP-SPAP responses
(pEC50 = 7.4 ± 0.1, Emax = 104.0 ± 15.0% of response to 1-μM NECA,
n = 5; Figure 9; Table 2).
4 | DISCUSSION
In the present study, we have investigated the effect of a novel
bitopic ligand VCP746, which has been reported to be a biased A1-
agonist (Valant et al., 2014), on cardiovascular responses in conscious,
freely moving rats. The aim was to establish whether a hybrid mole-
cule containing both adenosine and the positive allosteric enhancer,
VCP171, could provide a mechanism to activate a subset of A1-recep-
tor-mediated responses in particular vascular beds. The selective A1-
receptor agonist, CCPA, exhibited the full range of A1-mediated car-
diovascular responses leading to bradycardia, vasoconstriction in the
renal and mesenteric vascular beds, an increase in vascular conduc-
tance in the hindquarters and a fall in mean arterial pressure. The
small increase in vascular conductance in the hindquarters was only
mediated at the highest dose of CCPA and could be due to activation
of A2A- or A2B-receptors. The decrease in this effect by DPCPX did
F IGURE 9 Pharmacological evaluation of agonist-mediated CRE-SPAP gene transcription responses to VCP746 and NECA in CHO-K1 cells
expressing a CRE-SPAP reporter gene and (a) the human A2A-receptor or (b) the human A2B-receptor. Responses to NECA are shown as red
circles and VCP746 as blue circles. Data points represent mean ± SEM of five separate experiments (n = 5), each performed in quadruplicate. Data
have been expressed as a percentage of the response to 1-μM NECA measured in the same experiment. Curves through the data points were
fitted by non-linear regression analysis as described under Section 2. *P < .05 with respect to basal levels (one-way ANOVA)
TABLE 2 Concentration–response parameters for the agonist effects of NECA and VCP746 on CRE-mediated gene expression in CHO-K1
cells expressing either the human A2A- or A2B-receptors
A2A-receptor A2B-receptor
pEC50 Emax n pEC50 Emax n
NECA 7.50 ± 0.17 102.4 ± 6.1 5 7.29 ± 0.17 107.1 ± 2.6 5
VCP746 7.38 ± 0.07 104.0 ± 15.0 5 8.69 ± 0.11 103.0 ± 4.6 5
Note. Data are expressed as mean ± SEM in n separate experiments, performed in quadruplicate. Emax values are expressed as a percentage of the
response to 1-μM NECA measured in the same experiment.
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not reach statistical significance but could be related to the known
ability of DPCPX to antagonize A2B-receptors (pKB of 7.87; Vecchio
et al., 2016). The fall in mean arterial pressure caused by CCPA was
delayed compared to the effects of this A1-agonist on heart rate and
the vasoconstriction in the renal and mesenteric vascular beds and
may well be a consequence of the similarly delayed vasodilatation in
the hindquarters.
These responses, however, were very similar to those reported
by Jolly et al. (2008) with another A1-selective agonist (2-methyl-
CCPA). Interestingly, the lower efficacy A1-agonist, capadenoson
(Albrecht-Kupper et al., 2012; Tendera et al., 2012), produced a dose-
dependent decrease in HR (which was sensitive to inhibition by
DPCPX), but this was not accompanied by significant changes in the
other A1-receptor-mediated cardiovascular responses. These data
suggest that adenosine A1-responses in different parts of the cardio-
vascular system may well be subject to different signalling
efficiencies.
To determine whether differences in signalling efficiency or pref-
erential activation of particular signalling pathways (i.e., via biased-
agonism) can be exploited by a bitopic ligand, such as VCP746, we
have investigated the effect of this ligand in conscious rats subject to
normal autonomic reflex control. Previous work in isolated rat atria
showed that VCP746 did not produce the normal A1-receptor-
mediated negative chronotropic effect, but it was able to reduce
ischaemic damage, hypertrophy and remodelling in cardiomyocytes
(Chuo et al., 2016; Valant et al., 2014). Application of VCP746, how-
ever, produced a significant increase in HR in conscious, freely moving
rats that occurred in parallel with marked increases in renal and mes-
enteric vascular conductance. These effects were the complete oppo-
site of those expected of an A1-receptor agonist and were not
inhibited by the selective A1-antagonist DPCPX.
The responses to VCP746 were in many respects similar to those
elicited by adenosine, which produced tachycardia, increased vascular
conductance in all three vascular beds and a substantial fall in mean
arterial BP. All of these effects of adenosine were unaffected by
DPCPX treatment and were very similar to those reported by Jolly
et al. (2008) for adenosine using a similar conscious rat model.
VCP171, at doses that were the equimolar equivalent of those
found in pharmacologically active doses of VCP746, did not produce
any major changes in the responses to adenosine. VCP171 certainly
did not markedly enhance the contribution of A1-receptors in the final
response, with the possible exception of a small effect on heart rate.
VCP171 does not produce a large enhancement of the affinity of
adenosine at the rat A1-receptor (Cooper et al., 2019) and it is likely
that the positive A1-receptor allosteric action of the VCP171 entity
within the larger VCP746 molecule is not sufficient to overcome the
apparently more potent effect of the adenosine moiety on adenosine
A2A- or A2B-receptors in the cardiovascular system. This finding points
to the need swap adenosine for a more A1-selective agonist within
any future bitopic ligands and to match carefully the concentration
range over which the orthosteric and allosteric components operate.
It is also worth pointing out that the probe dependence of allosteric
modulators also needs to be considered (Cooper et al., 2019). For
example, VCP171 does not produce a significant positive allosteric
effect on the binding of capadenoson to the rat A1-receptor (Cooper
et al., 2019).
Cardiovascular responses to adenosine in the heart (via both A1-
and A2A-receptors) are complex with an A1-mediated reduction in
heart rate balanced by a A2A-mediated increase in heart rate (Evoniuk,
Jacobson, Shamim, Daly, & Wurtman, 1987; Jolly et al., 2008). It is
worth noting that A2A-receptors are also found in the cardiovascular
regulatory regions of the brain (Thomas, St Lambert, Dashwood, &
Spyer, 2000). Thus, an action at adenosine receptors in both the brain
and the periphery is likely to contribute to the overall effect of sys-
temically administered adenosine (Schindler et al., 2005). Further-
more, A2A-receptor effects on the heart have been proposed to be
partly not only due to a baroreceptor reflex response to the A2A-
receptor-mediated vasodilatation (Alberti et al., 1997; Barraco, Janusz,
Polasek, Parizon, & Roberts, 1988; Ohnishi, Biaggioni, Deray,
Branch, & Jackson, 1986; Thomas et al., 2000) but also due to a direct
activation of A2A-receptors in the heart (Lappe, Sheldon, & Cox, 1992)
and the CNS (Schindler et al., 2005). Lappe et al. (1992) have also
shown that systemic administration of an A2A agonist produces larger
increases in heart rate in conscious animals than anaesthetized ani-
mals. It is therefore likely that in conscious animals, the A1-mediated
effects on heart rate are masked by a greater contribution from A2A-
receptors via central A2A-receptors and via baroreceptive mecha-
nisms. This balance of A1- and A2A-responses (and the role of reflex
mechanisms) in conscious animals may also explain the lack of effect
of VCP746 on heart rate in isolated rat atria (Valant et al., 2014).
It has been shown previously that VCP746 is a potent and high
efficacy agonist at adenosine A2B-receptors (Vecchio et al., 2016).
However, the potent vasodilator and tachycardia effects of both
VCP746 and adenosine observed in the present study seem more
consistent with an effect on A2A-receptors (Alberti et al., 1997; Borea
et al., 2018; Headrick et al., 2013). As mentioned above, A2A-receptor
effects on heart rate have been proposed to be due to both barore-
ceptor reflex responses to A2A-receptor-mediated vasodilatation
(Barraco et al., 1988; Ohnishi et al., 1986; Thomas et al., 2000) and
direct activation of A2A-receptors in the heart (Lappe et al., 1992) and
brain (Schindler et al., 2005). However, in the case of activation by
VCP746, there was no change in mean arterial BP, suggesting that its
effects are due to direct activation of A2A-receptors in the heart and
CNS or alternatively a consequence of A2B-receptor activation.
To establish whether VCP746 has agonist activity at A2A-recep-
tors, in addition to its reported A2B-effect, we investigated its ability
to stimulate cAMP response element reporter gene responses in
CHO-K1 cells expressing either the human A2A-receptor or the human
A2B-receptor. In keeping with previous published work (Vecchio et al.,
2016), VCP746 was nearly two orders of magnitude more potent than
NECA at activating A2B-receptor. However, as predicted from the
in vivo cardiovascular data obtained in the present manuscript,
VCP746 was also a potent and high efficacy agonist of A2A-mediated
CRE-SPAP responses. An agonist effect of VCP746 on cAMP forma-
tion at A2A-receptors has also been reported recently in CHO cells
(Aurelio et al., 2018).
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In summary, the present study has shown that the bitopic ligand,
VCP746, does not stimulate cardiovascular responses that are medi-
ated by the adenosine A1-receptor. In contrast, it produces a marked
increase in heart rate and vascular conductance in both the renal and
mesenteric circulation that were opposite to those expected of an A1-
agonist. Studies of cAMP-mediated gene transcription responses in
CHO-K1 cells have confirmed that VCP746 is a potent and efficacious
agonist of the adenosine A2A-receptor, in addition to its known
actions at the A1- and A2B-receptors. Taken together, these data sug-
gest that the cardiovascular responses to VCP746 are mediated by
stimulation of cardiovascular A2A- or A2B-receptors rather than A1-
receptors. This has implications for the design of future bitopic ligands
that incorporate A1 allosteric ligand moieties to overcome on-target
cardiovascular side effects of drugs designed as A1-agonists for the
treatment of ischaemic heart disease.
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